ZyVersa Therapeutics, Inc.
ZVSA evidence brief
What we can confirm
- Market Cap:
- $801K
What it means
What to watch
Prepared research question
What matters most for ZVSA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ZVSA
ZyVersa Therapeutics, Inc. (ZVSA) is a clinical-stage biopharmaceutical company developing two proprietary platforms—VAR 200 for renal diseases and IC 100 for inflammatory conditions—with no approved products or revenue to date.
Key risk: No revenue or profitability
Market Cap
$801K
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Mar 31, 2026.
Tracking 1 clinical trial for ZyVersa Therapeutics, Inc..
ZyVersa Therapeutics, Inc. (ZVSA) is a clinical-stage biopharmaceutical company developing two proprietary platforms—VAR 200 for renal diseases and IC 100 for inflammatory conditions—with no approved products or revenue to date.
- ZyVersa is a clinical-stage biopharmaceutical company leveraging two proprietary platforms: Cholesterol Efflux Mediator VAR 200 for renal diseases and Inflammasome ASC Inhibitor IC 100 for inflammatory conditions [sec_mda · as of 2026-03-31].
- The lead indication for VAR 200 is focal segmental glomerulosclerosis (FSGS); an IND was filed in January 2020 and the FDA allowed Phase 2a planning [sec · filed 2025-04-17].
- IC 100 is in preclinical development with a planned IND submission in H2-2025, followed by a Phase 1 trial in healthy overweight patients [sec · filed 2025-04-17].
- As of 2026-03-31, the company reported a net loss of -$1.8M and negative shareholders' equity of -$14.1M [sec].
- ZyVersa has never been profitable, has no products approved for commercial sale, and has not generated any revenue from product sales [sec_mda · as of 2026-03-31].
What works
- ZyVersa has two proprietary, globally licensed drug development platforms with potential for multiple indications, which could maximize commercial value if successful [sec · filed 2025-04-17].
- The company has an FDA-allowed IND for VAR 200 in FSGS, indicating regulatory acceptance of the risk/benefit profile for Phase 2a planning [sec · filed 2025-04-17].
- IC 100 has generated preclinical data in six different animal models, demonstrating attenuation of pathogenic inflammasome signaling pathways [sec · filed 2025-04-17].
What to weigh
- ZyVersa has never been profitable, has no approved products, and has not generated any revenue from product sales; accumulated net loss was approximately $204 million as of December 31, 2025 [sec_mda · as of 2026-03-31].
- The company's cash position and ability to fund R&D are uncertain; it relies on current cash, future equity/debt financings, or strategic transactions [sec_mda · as of 2026-03-31].
- Development timelines are highly uncertain; the company notes that there can be no assurances that events will be completed on the anticipated timeline or at all [sec_mda · as of 2026-03-31].
From the filings
Quoted directly from source documents.
ZyVersa has never been profitable and has no revenue from product sales.
“We have never been profitable. To date, we do not have data to support regulatory approval of any of our drug products, we have no products approved for commercial sale in any jurisdiction, and we have not generated any revenue from product sales.”
SEC MD&A · March 31, 2026
VAR 200 IND was allowed by FDA for Phase 2a planning in FSGS.
“On January 21, 2020, we filed an Investigational New Drug application ("IND") for VAR 200, and the United States Food and Drug Administration ("FDA") has allowed our development plans to proceed to a Phase 2a trial in patients with FSGS based on the risk/benefit profile of the active ingredient (2HPβCD).”
SEC filings · April 17, 2025
IC 100 has preclinical data in six indications.
“IC 100 has preclinical data in animal models representing six different indications, each demonstrating that IC 100 attenuates pathogenic inflammasome signaling pathways leading to reduced inflammation and improved histopathological and/or functional outcomes.”
SEC filings · April 17, 2025
Accumulated net loss was approximately $204 million as of December 31, 2025.
“As of December 31, 2025, our accumulated net loss was approximately $204 million, inclusive of the period prior to the Business Combination period.”
SEC MD&A · March 31, 2026
Risks & what to watch (3)›
Key risks
- No revenue or profitability — ZyVersa has never been profitable, has no approved products, and has not generated any revenue from product sales [sec_mda · as of 2026-03-31].
- Uncertain cash runway — The company relies on current cash, future financings, or strategic transactions to fund R&D; no guaranteed funding source [sec_mda · as of 2026-03-31].
- Development timeline uncertainty — There are no assurances that clinical events will be completed on the anticipated timeline or at all [sec_mda · as of 2026-03-31].
What to watch
- IND submission for IC 100 planned in H2-2025 [sec · filed 2025-04-17].
- Initiation of Phase 1 trial for IC 100 in healthy overweight patients with BMI 27-30 [sec · filed 2025-04-17].
- Any updates on VAR 200 Phase 2a trial initiation in FSGS [sec · filed 2025-04-17].
- Changes in cash position and financing activities as reported in future SEC filings [sec_mda · as of 2026-03-31].
Sources: SEC filings · SEC MD&A · Generated October 8, 2026 · How we verify sources →
Run ZyVersa Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ZyVersa Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Sep 2025Institutional holders
1
Total value held
$1
| Holder | Shares | Value |
|---|---|---|
| guerra advisors inc | 7 | $1 |
Short Interest
as of Apr 22, 2026- % of float
- 7.4%
- Days to cover
- 0.3
- Shares short
- 359,252
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ZVSA short interestGovernance
Frequently asked questions
What is the AI investment thesis for ZyVersa Therapeutics, Inc.?
ZyVersa Therapeutics, Inc. (ZVSA) is a clinical-stage biopharmaceutical company developing two proprietary platforms—VAR 200 for renal diseases and IC 100 for inflammatory conditions—with no approved products or revenue to date.
Who is the CEO of ZyVersa Therapeutics, Inc.?
Mr. Stephen C. Glover is the chief executive officer of ZyVersa Therapeutics, Inc. (ZVSA).
Where is ZyVersa Therapeutics, Inc. headquartered?
ZyVersa Therapeutics, Inc. (ZVSA) is headquartered in Weston, FL, United States.
What therapeutic areas does ZyVersa Therapeutics, Inc. focus on?
ZyVersa Therapeutics, Inc. develops therapies across Metabolic, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.